Scientific Advisory Board

Catherine Lubetzki

Chair of Advisory Board, Professor of Neurology at Sorbonne University, Head, Department of Neurology and Coordinator of the MS center in Salpêtrière Hospital, Paris, France

Catherine Lubetzki leads a research group in the Brain and Spinal cord Institute (ICM) within the Salpetriere campus, together with Prof Bruno Stankoff. The aim of this translational research team is to develop strategies to prevent neurodegeneration and reduce disability progression in Multiple Sclerosis patients, by combining basic sciences of neuroglial cells, identification of pro-myelinating candidates and imaging of myelin loss and repair.

She is or has been involved in several committees and funding boards: member of ECTRIMS (European congress on multiple sclerosis) executive committee, past-president of the scientific committee of ARSEP (French multiple sclerosis association for research), member of the International Progressive MS Alliance Scientific Steering Committee. She is elected chair for the next Gordon Research Conference in myelin. She acts as vice president of Sorbonne University Foundation.

Her clinical activity is mainly dedicated to the management of multiple sclerosis patients, the department of Neurology being the most important clinical center for multiple sclerosis in France, with a very large active file and a very active clinical research activity.

Wolfgang Brück

Professor of Neuropathology and Head of the Department of Neuropathology, University Medical Center Göttingen, Germany

Wolfgang Brück is a highly respected clinician-scientist whose work focuses on the structural features and immunopathology of multiple sclerosis (MS), in particular on the mechanisms of degeneration (myelin, oligodendrocytes, axons neurons) and regeneration, namely remyelination in MS lesions. He has been in his current role at the University Medical Centre Göttingen, Germany since 2002, and is also on the SABs of the Cambridge Centre for Myelin Repair, University of Cambridge, UK, the Edinburgh Centre for Translational Research, UK, and The Myelin Project. He has received various awards for his contributions to research in MS, including the Langheinrich Award for Multiple Sclerosis Research (2000), the Hans Heinrich Georg Queckenstedt Award for Multiple Sclerosis Research (2002), the HG Mertens Prize for Innovative Research in Neurology (2008), and the Kohn Memorial Lecture Prize from the British Society of Toxicological Pathology (2011).

Giancarlo Comi

Professor of Neurology, Chairman of the Department of Neurology, and Director of the Institute of Experimental Neurology at Vita-Salute San Raffaele University, Milan, Italy

Giancarlo Comi brings world-renowned expertise in multiple sclerosis. In addition to his role at Vita-Salute San Raffaele University, he is President of the European Charcot Foundation (ECF), a member of the Board of Administration of the Italian Multiple Sclerosis Foundation and of the Scientific Committee of Associazione Italiana Sclerosi Multipla, Co-Chair of the Scientific Steering Committee of the Progressive MS Alliance, and a fellow of the European Academy of Neurology (EAN). In recent years, he has been awarded honorary memberships of the Russian Neurological Academic Society, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the European Neurological Society (ENS) and the Sociedad Espanola de Neurologia.

Robin Franklin

Professor of Stem Cell Medicine, Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Director of the UK MS Society Cambridge Centre for Myelin Repair at the University of Cambridge

Robin Franklin is currently Professor of Stem Cell Medicine at the University’s Clinical School, having previously been Professor of Neuroscience in the University’s School of Biology. He obtained his undergraduate degrees in Physiology and Veterinary Medicine at the University of London and his PhD in Neuroscience at the University of Cambridge. His main research questions are how stem cells in the adult brain respond to injury, how do they contribute to regeneration, and how are they are affected by ageing? He has published over 260 peer-reviewed papers and is internationally recognized as a leader and pioneer in the field of remyelination biology. He was the recipient of the 2017 Barancik International Prize for Research Innovation and is a Fellow of the Academy of Medical Sciences.

Daguang Wang

Managing Director of Yonjin Capital, the North America and Europe investment arm of Yonjin Group in Shanghai, China

Daguang Wang combines expertise in neuroscience discovery with board-level leadership experience. Before moving into venture investment, he spent more than 20 years in the biotech and pharmaceutical industry with Amgen, Memory Pharmaceuticals, PsychoGenics, EMD Serono and Sanofi. Dr. Wang started his career as an R&D scientist in neuroscience, before moving to business development and external innovation with a focus on neuroscience, multiple sclerosis and rare diseases. He was global lead of business development and external innovation for neuroscience at Sanofi before joining Yonjin Capital in 2018. He serves on the boards of multiple start-up biotech companies.